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Background:  Coronary atherosclerosis (ATS) progression has important clinical implications. Recent studies have shown that serum levels of 
gamma-glutamyltransferase (GGT) predict the risk of cardiovascular events and may be directly associated with ATS progression by its effects on 
lipidic profile, oxidative status and apoptosis modulation. We aimed at assessing predictors of ATS progression, including GGT levels, in ischemic 
patients on full medical treatment, including statins, undergoing follow-up (FU) coronary angiography.
Methods:  100 consecutive anginal patients (age 64+/-11, male sex 68 %) undergoing two clinically (Stable Angina or Acute Coronary Syndrome) 
driven coronary angiographies separated by at least six months and found to have coronary ATS were prospectively enrolled between May 2008 and 
June 2010. The extent of coronary ATS was graded according to Bogaty’s score at both coronary angiographies and the variation (Δ) in extent index 
between FU (E2) and basal values (E1) was calculated for each patient. Predictors of Δ E2-E1 were assessed among clinical data recorded at the 
time of the first coronary angiography, and laboratory data, including GGT levels, analyzed as Δ between FU and basal values.
Results:  Sixty-three patients presented with SA (65+/-10, male sex 78%) and 37 patients presented with acute coronary syndrome (61+/-11, 
male sex 51%) at the first coronary angiography.
Δ GGT2-1 levels and Δ E2-1 in the overall population were 1.0 +/- 0.7 and 1.40 +/-0.7, respectively, and were similar between SA and ACS patients 
(p=NS). At univariate analysis a significant correlation was found between Δ GGT2-1 levels and Δ E2-1 (r=0.219, p=0.03). Additionally, among 
clinical data, smoking habit tended to be associated with higher Δ E2-1 (p=0.07). At multivariate analysis, the only independent predictor of Δ E2-1 
was Δ GGT2-1 (B=0.505, SE=0.206, p=0.01).
Conclusion: Our data demonstrate that GGT levels predict angiographic coronary ATS progression in patients affected by ischemic heart disease 
and treated with current guidelines indicated therapy. Our finding may be clinical utility for identification of new therapeutic targets against ATS 
progression.
